

Laura San-Segundo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8325977/publications.pdf>

Version: 2024-02-01

36
papers

1,176
citations

471509

17
h-index

434195

31
g-index

37
all docs

37
docs citations

37
times ranked

2865
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. <i>Leukemia</i> , 2015, 29, 2110-2113.	7.2	170
2	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	3.5	144
3	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. <i>Blood</i> , 2013, 122, 3591-3598.	1.4	131
4	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , 2009, 113, 3781-3791.	1.4	78
5	The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. <i>Oncotarget</i> , 2015, 6, 18875-18890.	1.8	74
6	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , 2015, 29, 705-714.	7.2	72
7	Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development. <i>Journal of Hematology and Oncology</i> , 2016, 9, 113.	17.0	72
8	Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. <i>Leukemia</i> , 2015, 29, 1186-1194.	7.2	71
9	The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. <i>Clinical Cancer Research</i> , 2017, 23, 225-238.	7.0	42
10	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. <i>Haematologica</i> , 2020, 105, e116-e120.	3.5	38
11	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , 2012, 97, 1110-1114.	3.5	34
12	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 6602-6615.	7.0	25
13	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. <i>Journal of Hematology and Oncology</i> , 2017, 10, 127.	17.0	25
14	C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis. <i>Oncotarget</i> , 2017, 8, 110994-111011.	1.8	24
15	Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138 ⁺⁺ and CD138 ^{low} Subpopulations in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2014, 9, e92378.	2.5	23
16	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. <i>Leukemia</i> , 2020, 34, 1599-1612.	7.2	21
17	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017, 102, 2113-2124.	3.5	19
18	Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control. <i>British Journal of Haematology</i> , 2016, 173, 754-768.	2.5	18

#	ARTICLE	IF	CITATIONS
19	CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition. <i>Blood</i> , 2018, 132, 948-948.	1.4	17
20	PTPN13 and β -Catenin Regulate the Quiescence of Hematopoietic Stem Cells and Their Interaction with the Bone Marrow Niche. <i>Stem Cell Reports</i> , 2015, 5, 516-531.	4.8	15
21	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , 2011, 96, 687-695.	3.5	13
22	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. <i>Haematologica</i> , 2017, 102, 168-175.	3.5	9
23	Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2743.	3.7	9
24	A Novel Murine Model of Human Disseminated Multiple Myeloma with A Subcutaneous Human Bone Chip from an Adult Donor Confers Proliferative Advantage and Is Suitable for the In Vivo Evaluation of Novel Drugs. <i>Blood</i> , 2010, 116, 4077-4077.	1.4	9
25	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 257-269.	1.8	7
26	The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies. <i>Blood</i> , 2014, 124, 2100-2100.	1.4	4
27	Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7518.	4.1	4
28	Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM. <i>Blood</i> , 2011, 118, 134-134.	1.4	3
29	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. <i>Cells</i> , 2021, 10, 559.	4.1	2
30	Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism. <i>Blood</i> , 2015, 126, 5353-5353.	1.4	1
31	The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone. <i>Blood</i> , 2015, 126, 5354-5354.	1.4	1
32	Phenotypic, Functional and Circadian Characterization of Peripheral Blood (PB) Multiple Myeloma (MM) Circulating Tumor Cells (CTCs). <i>Blood</i> , 2012, 120, 726-726.	1.4	0
33	Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs. <i>Blood</i> , 2014, 124, 4710-4710.	1.4	0
34	Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1801-1801.	1.4	0
35	Prognostic Implications of PIM-2 Expression in Samples from Patients with Chronic Lymphocytic Leukemia and Impact in the Sensitivity to the Pan-PIM Kinase Inhibitor PIM447. <i>Blood</i> , 2015, 126, 2923-2923.	1.4	0
36	Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment. <i>Blood</i> , 2018, 132, 954-954.	1.4	0